Influenza Vaccine Market Size, Share, Trends And Forecast To 2032

What is the Market size of the Influenza Vaccine Industry?

According to the report published by Zion Market Research, the global Influenza Vaccine Market size was valued at USD 8.06 Billion in 2023 and is predicted to reach USD 14.94 Billion by the end of 2032. The market is expected to grow with a CAGR of 7.1% during the forecast period. The report analyzes the global Influenza Vaccine Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Influenza Vaccine industry.

Request Free Sample

Global Influenza Vaccine Market: Overview

The viral infection is caused due to the flu known as influenza in the respiratory system. Influenza virus enters the human body with the help of respiratory droplets and is contagious. It can spread from one person to another with physical contact or random face-to-face communication. The influenza virus keeps on circulating in the whole body continuously, along with the several outbreaks and regional epidemics that lead to severe death cases. The transforming building structure of the virus is inducing a massive change in vaccines to match the blueprint of changing influenza virus strain. The medicare organizations across the globe, including the centers for disease control and prevention, are advising several vaccines like baloxavir marboxil (Xofluza) for treating such flu or influenza in the body. The vaccines developed for treating influenza are made in combination of three different viruses, including influenza type A with H1N1, type B virus strain, and influenza type A H3N2 virus strain.

Global Influenza Vaccine Market: Growth Factors

The growing prevalence of influenza epidemics is likely to steer the growth of the global influenza vaccine market during the forecast period. The frequent seasonal outbreaks globally are further likely to expand the sales of such vaccine products over the projected period. The constantly growing government support and favorable policies regarding vaccination against viruses like influenza on the global level are likely to further support the market growth.

Furthermore, the government effectively administers and monitors the distribution and supply of flu vaccines. Market players are fuelling the investments and the government is also rising its funding to launch therapeutically advanced and effective vaccines for influenza. The immunization programs and camps are conducted by several medical organizations. However, vaccine development is a very tedious and time taking process that generally ranges from around 10 to 15 years to establish the efficacy and safety of vaccines.

But several regulatory amendments and modifications are done in several countries to avoid the delay in the development of vaccines, which in turn is likely to be the crucial factor for the development of the global influenza vaccine market. Companies are highly involved in research and development activities to bring innovative vaccines to the market. The outbreak of the Covid-19 pandemic globally is likely to fuel the demand for influenza vaccines in the market. However, it has significantly led people to take vaccines even in the normal flu as a precautionary action.

Request Free Sample

Global Influenza Vaccine Market: Segmentation

The global influenza vaccine market can be segmented into age group, technology, type, vaccine type, route of administration, and region.

By age group, the market can be segmented into pediatric and adults.

By technology, the market can be segmented into cell-based and egg-based. The cell-based segment holds the largest share in the global influenza vaccine market owing to the significant spike in surgical procedures all around the world.

By type, the market can be segmented into seasonal and pandemic. The seasonal influenza vaccine segment dominates the global influenza vaccine market owing to the high consumption of influenza vaccines more frequently in changing seasons. However, the pandemic influenza vaccine segment is expected to be the fastest-growing region in the global influenza vaccine market due to the outbreak of the Covid-19 pandemic globally.

By vaccine type, the market can be segmented into trivalent and quadrivalent. The quadrivalent segment accounts for the largest share in the global influenza vaccine market due to its easy availability, high efficacy against viral infections, and cost-effectiveness.

By route of administration, the market can be segmented into nasal spray and injection.

Recent Developments:

• In June 2025, the Pan American Health Organization (PAHO) partnered with the Ministry of Health Guyana to support the implementation of seasonal influenza vaccination in the country. The collaboration includes plans to conduct seasonal influenza vaccination campaigns during the latter quarter of 2025.
• In March 2024, Osivax announced that all participants had completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, its broad-spectrum influenza A vaccine candidate, including its potential use within quadrivalent influenza vaccines (QIVs).
• In October 2023, BioNTech SE and Pfizer Inc. announced positive Phase 1 study results for an mRNA-based combination vaccine targeting both influenza and COVID-19.

Influenza Vaccine Market: Report Scope

Global Influenza Vaccine Market: Regional analysis

North America accounts for the largest share in the global influenza vaccine market due to the high prevalence of infectious diseases in the region. In addition, the growing awareness among people regarding the influenza vaccine will further accentuate the demand in the regional market. Also, the devastating impact of the Covid-19 pandemic in the region is posing a huge demand for influenza vaccines. Furthermore, the region is likely to be the largest consumer of these vaccines in the forthcoming years. The constantly growing geriatric population in the region will also pose a large-scale demand for influenza vaccines.

Asia Pacific is expected to be the fastest-growing region in the global influenza vaccine market due to the presence of prominent market leaders in the region. Also, the outbreak of the Covid-19 pandemic in the region has led the governments to focus on influenza and flu vaccines to combat the surging symptoms amid this pandemic.

Global Influenza Vaccine Market: Competitive Players

Some of the significant players in the global influenza vaccine market are

• Sinovac Biotech Ltd.
• Sanofi
• Pfizer, Inc.
• Novartis Ag
• Merck & Co., Inc.
• GlaxoSmithKline Plc
• Gamma Vaccines Pty Ltd.
• F. Hoffmann-La Roche Ltd.
• Emergent Biosolutions
• Csl Limited
• Biodiem
• AstraZeneca Plc.

The Global Influenza Vaccine Market segments are as follows:

By age group

• pediatric
• adults.

By technology

• cell-based
• egg-based.

By type

• seasonal
• pandemic

By vaccine type

• trivalent
• quadrivalent.

By route of administration,

• nasal spray
• injection.

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.